Symphera
Key Facts
| Invested since | 2024 |
| Based in | Bavaria |
About the company
Symphera is a Munich-based startup that is revolutionizing laparoscopic surgery with an innovative system designed to eliminate the need for manual instrument changes. Founded in 2023, Symphera was incubated at TU Munich and UnternehmerTUM, originating from the University Hospital in Basel, where Dr. med. Conrad Heid, co-founder of Symphera, has been a practicing laparoscopic surgeon. The company’s vision is to significantly simplify the surgical workflow, ultimately leading to greatly improved post-operative outcomes for patients.
Do you want to
know more about this company?
Symphera in the news
More startups from Life Sciences
Exit
cytena’s single-cell printer is a unique device for separating, sorting and handling of single biological cells. For the first time this method enables an automated, separation of single cells with …
To the complete profileof Cytena
Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.
To the complete profileof ALGIAX
TRIM TX is developing best-in-class Gamma-Secretase-Stabilizers (GSS) for the prevention and treatment of Alzheimer Disease.
To the complete profileof TRIM TX
Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA …
To the complete profileof Pantherna Therapeutics
Carelane is a health tech startup focused on addressing the inefficiencies in clinical trials by integrating multiple essential functions into a single, streamlined system, thereby digitizing study protocols and processes. …
To the complete profileof Carelane
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
To the complete profileof PreComb
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
To the complete profileof Draupnir Bio
HBOX Therapies has developed a technology that facilitates lung-protective treatment of respiratory patients, the patented platform technology HBOX (Hyperbaric Blood Oxygenation). The management team of HBOX Therapies consists of the …
To the complete profileof HBOX Therapies
Exit
Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …
To the complete profileof CARDIOR
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
To the complete profileof Provecs Medical
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and …
To the complete profileof Nebula Biocides
Exit
Humedics markets a system for bedside and instantaneous measurement of liver function. Patented device, consumables and a diagnostic drug allow an optimal market offering.
To the complete profileof Humedics